Costimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
US-2018179281-A1 · Jun 28, 2018 · US
Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
US11242387B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11242387-B2 |
| Application number | US-201916544357-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 19, 2019 |
| Priority date | Oct 6, 2004 |
| Publication date | Feb 8, 2022 |
| Grant date | Feb 8, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of inhibiting expression of B7-H1 in a tumor cell of a subject, the method comprising: (a) identifying the subject as having a renal cell carcinoma wherein ≥10% of the tumor cells of the renal cell carcinoma express B7-H1; and (b) introducing into the tumor cell of the subject: (i) an antisense oligonucleotide that hybridizes to a B7-H1 transcript, wherein the antisense oligonucleotide inhibits expression of B7-H1 in the tumor cell; or (ii) a B7-H1 interference RNA (RNAi).
Assignees
Inventors
Classifications
of other specific parts of the body, e.g. brain · CPC title
of the liver or pancreas · CPC title
involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title
- C12N15/1138Primary
against receptors or cell surface proteins · CPC title
IFN-alpha · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11242387B2 cover?
- The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.
- Who is the assignee on this patent?
- Mayo Found Medical Education & Res
- What technology area does this patent fall under?
- Primary CPC classification C12N15/1138. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).